Visit The Valens Company Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors.
The Valens Company Secures CAD$40 Million Term Loan
Non-dilutive debt capital provides Valens with greater flexibility in its growth strategy in Canada and United States
KELOWNA, BC, Dec. 16, 2021 /PRNewswire/ – The Valens Company Inc. (TSX: VLNS) (Nasdaq: VLNS) (the “Company” “The Valens Company” or “Valens”), a leading manufacturer of cannabis products, announces that it has entered into a secured non-revolving term loan (the “Loan Agreement”) with 2361380 Ontario Limited , a private institutional lender, for an aggregate principal amount up to CAD$40 million (the “Loan”). The Loan will accrue interest at a rate of 10% per annum, payable quarterly, and matures on December 15, 2023 with an initial interest payment date on December 31, 2021. Proceeds from the Loan will further strengthen the Company’s balance sheet, allowing it to execute on its corporate strategy and fund working capital needs as the business continues its aggressive growth trajectory, as well as immediately retire the remaining $7.5 million outstanding under its existing debt facility.
With this strategic secured financing, Valens is now well positioned to accelerate its aggressive growth strategy, further fund its Canadian operations, and capitalize on new growth opportunities as the Company works toward expanding its presence in the United States.
Tyler Robson, Chief Executive Officer and Chairman of The Valens Company
This CAD$40 million Term Loan reflects the unique value proposition that Valens has created in the market, as well as the continued confidence from our management, board, and shareholders in the continued execution of our business plan.
Jeff Fallows, President of The Valens Company said: “This is a very attractive cost of capital and a non-dilutive financing solution that provides more financial flexibility, fewer covenants and restrictions and better enables us to aggressively penetrate our target markets and create shareholder value. This transaction, not only funds our current business plan but also strengthens our balance sheet. As a result, we do not anticipate the need to raise additional equity capital in the near term.”
At Valens, it’s Personal.
About The Valens Company
The Valens Company is a leading manufacturer of cannabis products with a mission to bring the benefits of cannabis to the world. The Company provides proprietary cannabis processing services, in addition to best-in-class product development, manufacturing, and commercialization of cannabis consumer packaged goods. The Valens Company’s high-quality products are formulated for the medical, health and wellness, and recreational consumer segments, and are offered across all cannabis product categories with a focus on quality and innovation. The Company also manufactures, distributes, and sells a wide range of CBD products in the United States through its subsidiary Green Roads, and distributes medicinal cannabis products to Australia through its subsidiary Valens Australia. In partnership with brand houses, consumer packaged goods companies and licensed cannabis producers around the globe, the Company continues to grow its diverse product portfolio in alignment with evolving cannabis consumer preferences in key markets. Through Valens Labs, the Company is setting the standard in cannabis testing and research and development with Canada’s only ISO17025 accredited analytical services lab, named The Centre of Excellence in Plant-Based Science by partner and scientific world leader Thermo Fisher Scientific. Discover more on The Valens Company at http://www.thevalenscompany.com.
For fact-based information on The Valens Company, view the company’s sponsored Investor Dashboard.
Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.